PYLUM BIOSCIENCES, INC.

Capabilities

Pylum Biosciences has developed and patented the Avidocin platform technology, capable of generating batericidal protein complexes targeting specfic bacterial pathogens using a unique killing mechanism that is oblivious to CRISPR based resistance. Avidocin proteins can be quickly modified to kill emerging strains as their genome sequences become available. Our pipeline is focused on infectious diseases (eg C. diff) and oncology related pathogens (eg CRC).